Chapter 16 Biological Therapies in Canine Sports Medicine 413
Stem cells
Definitions and sources
The use of MSC therapies in veterinary patients
is a field that is evolving rapidly, both experimen‑
tally and clinically. MSCs have received increas‑
ing attention due to the potential of augmenting
healing of muscles, tendons, ligaments, and
bone. However, the lack of strict regulations has
led to the proliferation of commercially available
products and therapies that have either not been
tested or have not demonstrated efficacy. Many
questions remain unanswered, including the best
tissue source, best method of collection and prep‑
aration, ideal cell numbers, and best administra‑
tion technique. A summary of the sources of
various stem cell types, and their effects, clinical
uses, and limitations is provided in Table 16.1.
Stem cells are defined based on their ability to
differentiate into a wide range of cells and to self‐
renew. Stem cells can be classified in different
ways, although the classification based on the
source may be the most relevant for the clinician.
Embryonic stem cells are derived from embryos
at a developmental stage; induced pluripotent
cells are engineered by manipulating the expres‑
sion of certain genes; adult stem cells, applicable
to clinical uses, are undifferentiated multipotent
cells, found throughout the body after embryonic
development. Their function is to repair tissue
and replenish senescent cells. Among the adult
stem cells, MSCs have the important advantage of
being more readily available and easy to obtain
compared with embryonic and fetal stem cells.
Sources of MSCs include fetal tissue such as
umbilical cord, and blood and adult tissues such
as bone marrow, skin, adipose tissue, synovium,
periosteum, and dental pulp. Because tumor for‑
mation has been reported after application of
embryonic stem cells, potential adverse effects
include stem cell‐induced carcinogenesis and tis‑
sue formation. However, multipotent MSCs used
in most studies are in a more committed cell stage
and have far more limited differentiation poten‑
tial than totipotent embryonic stem cells. As a
result, there is no published evidence demonstrat‑
ing carcinogenesis of multipotent MSC in either
in vitro or in vivo models (Hernigou et al., 2013).
MSCs are undifferentiated cells that have
unique characteristics as they can (1) move dur‑
ing angiogenesis; (2) differentiate into special‑
ized cell types (e.g., chondrocyte, osteocyte); (3)
proliferate and regenerate; and (4) release
immune regulators and growth factors. More
specifically, MSCs are defined based on their
ability to differentiate in vitro into osteoblasts,
adipocytes, or chondroblasts, adhere to plastic,
and express specific genes. The first application
of MSC‐based therapy in veterinary medicine
was performed in horses using bone marrow
aspirate for treating suspensory ligament
desmitis. Bone marrow is an attractive source
for MSCs, although only a very small cellular
fraction corresponds to MSCs (<0.001%). For
this reason, culture expansion techniques over
Table 16.1 Comparison of stem cells from different sources: their effects, uses, and limitations
Hematopoietic stem cells Embryonic stem cells Mesenchymal (adult) stem cells
Source Bone marrow
(autologous or allogeneic)
Blastocysts/early embryo
(allogeneic)
Bone marrow, fat, cord blood
(autologous or allogeneic)
Potency Multipotent Pluripotent Multilineage differentiation
Beneficial
effects
Transplantation of healthy cells in
diseased individual
Source of biological
material for various cell
restorative treatments
Anti‐inflammatory; anti‐apoptotic;
differentiation into cartilage,
muscle, bone, nerve cells
Clinical
uses
Neoplastic disorders of blood and bone
marrow; autoimmune disease; skeletal
dysplasia; mucopolysaccharidosis
Potential for tissue
regeneration
Regeneration of several
tissues, e.g., tendons, neurons,
chondrocytes, cornea
Limitations Potential for graft versus host reaction Risk for tumor formation
Ethical concerns
Legal restrictions
Difficult to identify, isolate,
maintain, and culture